sgt-53
Gene therapyexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00470613)
Timeline
Indications
Mechanism of action
- Cellular tumor antigen p53Supplementation
TP53 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sgt-53
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07017816 | Early Phase 1 (Phase 1) | Jul 31, 2025 | Georgetown University |
| NCT03554707 | Early Phase 1 (Phase 1) | Sep 30, 2018 | Children's National Medical Center, SynerGene Therapeutics, Inc. |
| NCT02340117 | Phase 2 | Jan 1, 2015 | Mary Crowley Cancer Center, SynerGene Therapeutics, Inc. |
| NCT02340156 | Phase 2 | Dec 1, 2014 | SynerGene Therapeutics, Inc., University of Texas at Houston |
| NCT02354547 | Phase 1 | Dec 1, 2014 | Baylor University, SynerGene Therapeutics, Inc. |
| NCT00470613 | Phase 1 | Feb 1, 2008 | Mary Crowley Cancer Center, SynerGene Therapeutics, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SynerGene Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2008 |
| Mary Crowley Cancer Center | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Baylor University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Children's National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Georgetown University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1